Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data

Jeffrey A. Scott, Rushir J. Choksi|JCO Oncology Practice|2023

Cited by 53